Transcription factor RUNX2 regulates epithelial‑mesenchymal transition and progression in renal cell carcinomas

Renal cell carcinoma (RCC) is difficult to cure once it progresses and metastasizes. Runt‑related transcription factor 2 (RUNX2) is associated with the development or progression of various cancers, but its role in RCC remains unclear. The expression of RUNX2 is not only aberrantly increased in ccRC...

Full description

Saved in:
Bibliographic Details
Published inOncology reports Vol. 43; no. 2; pp. 609 - 616
Main Authors Liu, Bitian, Liu, Junlong, Yu, Hongyuan, Wang, Changming, Kong, Chuize
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications 01.02.2020
Spandidos Publications UK Ltd
Subjects
Cancer
Carcinoma
Cell adhesion & migration
Development and progression
Fluorides
Gene expression
Kidney cancer
Metastasis
Prognosis
Prostate cancer
Proteins
Renal cell carcinoma
Scientific equipment industry
Stem cells
Survival analysis
Transcription factors
Tumors
United States
China
Online AccessGet full text

Cover

More Information
Summary:Renal cell carcinoma (RCC) is difficult to cure once it progresses and metastasizes. Runt‑related transcription factor 2 (RUNX2) is associated with the development or progression of various cancers, but its role in RCC remains unclear. The expression of RUNX2 is not only aberrantly increased in ccRCC, but also is increased with increasing tumor stage and pathological grade. The prognosis of patients with tumors expressing RUNX2, which was revealed to be highly expressed in survival analysis, was significantly worse. Gene set enrichment analysis revealed that the RUNX2‑mediated epithelial‑mesenchymal transition (EMT) pathway promoted tumor progression. In vitro, knockdown of RUNX2 inhibited the proliferation, migration, and invasion of RCC, with related proteins in the EMT pathway exhibiting corresponding changes. RUNX2 regulated EMT in RCC to promote tumor progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1021-335X
1791-2431
DOI:10.3892/or.2019.7428